| Cat. No. |
Product Name |
Information |
| PC-Ab1012 |
Urelumab
|
Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic, enhances NK-cell activation increasing CD25 expression and IFNɣ production, but not in vitro ADCC. Urelumab enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab.. |
| PC-Ab1011 |
Anti-Human TIGIT mAb, 22G2
|
. |
| PC-Ab1010 |
Bevacizumab
|
A humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, inhibits its interaction with VEGFR-1 and VEGFR-2. Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with EC50 of 0.047 ug/ml. |
| PC-Ab1009 |
Trastuzumab
|
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.. |
| PC-Ab1008 |
Nivolumab
|
Nivolumab binds to the extracellular portion of human PD-1 (2.6 nM - Scatchard analysis and SPR) - the antibody also binds to cynomolgus PD-1 with a similar affinity (3.9 nM - SPR). The antibody does not bind to other immunoglobulin superfamily proteins such as CD28, CTLA-4, ICOS and BTLA. Nivolumab enhances immune response against various cancers. . |
| PC-Ab1007 |
M7824
|
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, attenuated features of TGF-β1-mediated mesenchymalization, including mesenchymal marker expression, proliferation suppression, and chemoresistance in vitro and in vivo.. |
| PC-Ab1006 |
Tiragolumab
|
The first anti-TIGIT (T-cell immunoglobin and ITIM domain protein) mAb, prevent TIGIT from binding to its ligand, could restore the antitumor response and could complement the activity of anti–PD-L1/PD-1 antibodies. Anti-TIGIT mAb (tiragolumab) has demonstrated promising clinical efficacy in non-small cell lung cancer treatment when combined with an anti-PD-L1 drug (Tecentriq), exhibited remarkable efficacy in PD-L1-positive NSCLC patients in phase II clinical trials.. |
| PC-Ab1005 |
Avelumab
|
Avelumab is a fully human IgG1 anti-PD-L1 mAb to programmed cell death receptor ligand 1 (PD-L1), which modulates T cell immune reactivity and is used in the immunotherapy of cancer. Avelumab has major side effects and particularly immune related conditions, including acute liver injury which can be serious and even life threatening.. |
| PC-Ab1004 |
Atezolizumab
|
A humanized monoclonal antibody to programmed death-ligand 1 (PD-L1) that increases immune reactivity to tumor neoantigens and is used as immunotherapy of selected cancers of the bladder and lung. increases immune reactivity to tumor neoantigens and is used as immunotherapy of selected cancers of the bladder and lung. Atezolizumab has been associated with a low rate of serum enzyme elevations during therapy and with uncommon instances of clinically apparent, immune-mediated liver injury.. |
| PC-Ab1003 |
Rituximab
|
The first monoclonal antibody approved for cancer therapy and the first single-agent approved for therapy of lymphoma. It was approved by the FDA for the treatment of patients with relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma in 1997.. |
| PC-Ab1002 |
Magrolimab
|
A monoclonal anti-human CD47 antibody by grafting its complementarity determining regions (CDRs) onto a human IgG4 format. |
| PC-Ab1001 |
Blinatumomab
|
Anti-Human CD3 CD19 BsAb (Blinatumomab biosimilar. |
